AKR1C1 and AKR1C2 were prognostic factors of breast cancer (Wenners et al., 2016), and selective loss of these genes may help enhance endocrine therapy in breast cancer (Ji et al., 2004). This evidence concerns the gene AKR1C2 and breast cancer.